Ansley Kahn is a senior program assistant at GHTC who supports GHTC's communications and member engagement activities.
Sign up to receive news and updates from GHTC.
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign-up now to receive our weekly R&D News Roundup email.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The latest Ebola outbreak in the Democratic Republic of Congo was officially
declared over last Tuesday, following a 42-day observation period since the last new case was reported. Health experts credit the use of an experimental
vaccine and a speedy and effective response by both the government and the World Health Organization as key factors in controlling this outbreak.
Two clinical studies revealed that GlaxoSmithKline’s two-drug treatment for HIV, a combination of dolutegravir and lamivudine, also known as 3TC, is as effective as the standard triple
therapy. Crucially, the studies showed that the efficacy of the treatment was consistent whether individuals had higher or lower levels of HIV in their
blood, dispelling notions that the two-drug regimen might not work as well in people with more virus. Questions remain regarding the durability of
treatment and potential drug resistance, given that the data only spans a 48-week period. The two-drug combination is slated for regulatory submission
later this year.
The US Food and Drug Administration approved the first new treatment for Plasmodium vivax malaria in 60 years.
The drug, tafenoquine, is a single-dose treatment developed by GlaxoSmithKline and Medicines for Malaria Venture. P. vivax malaria causes around 8.5
million infections every year in Asia, Latin America, and parts of Africa. The disease is tricky to combat because the P. vivax parasite can lie dormant
in the liver, where it reactivates, and can cause new episodes of malaria weeks, months, and years after the initial infection. In a study of 522 patients,
60 percent saw no relapse six months after taking the drug. Tafenoquine has been submitted for approval to the Australian regulatory authority and
is slated to be submitted for approval in malaria endemic countries.